Brief: RenovoRx to Present Preclinical Data For Its Platform's Potential Utility for Bile Duct Cancer Treatment
19/05/2022 14:45
May 19 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX TO PRESENT PRECLINICAL RESEARCH DATA
DEMONSTRATING ITS
INNOVATIVE THERAPY PLATFORM’S POTENTIAL UTILITY FOR THE
TREATMENT OF BILE DUCT CANCER
Source text for Eikon: ID:nBwbBLr16a
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies